199 related articles for article (PubMed ID: 30236129)
41. The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin.
Peng S; Liu XS; Huang S; Li Z; Pan H; Zhen W; Luk KD; Guo XE; Lu WW
Bone; 2011 Dec; 49(6):1290-8. PubMed ID: 21925296
[TBL] [Abstract][Full Text] [Related]
42. Effect of interleukin-32gamma on differentiation of osteoclasts from CD14+ monocytes.
Kim YG; Lee CK; Oh JS; Kim SH; Kim KA; Yoo B
Arthritis Rheum; 2010 Feb; 62(2):515-23. PubMed ID: 20112365
[TBL] [Abstract][Full Text] [Related]
43. The Effects of Aronia melanocarpa 'Viking' Extracts in Attenuating RANKL-Induced Osteoclastic Differentiation by Inhibiting ROS Generation and c-FOS/NFATc1 Signaling.
Ghosh M; Kim IS; Lee YM; Hong SM; Lee TH; Lim JH; Debnath T; Lim BO
Molecules; 2018 Mar; 23(3):. PubMed ID: 29518052
[TBL] [Abstract][Full Text] [Related]
44. (5R)-5-Hydroxytriptolide (LLDT-8) inhibits osteoclastogenesis via RANKL/RANK/OPG signaling pathway.
Shen Y; Jiang T; Wang R; He S; Guo M; Zuo J; He D
BMC Complement Altern Med; 2015 Mar; 15():77. PubMed ID: 25887296
[TBL] [Abstract][Full Text] [Related]
45. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation.
Quinn JM; Horwood NJ; Elliott J; Gillespie MT; Martin TJ
J Bone Miner Res; 2000 Aug; 15(8):1459-66. PubMed ID: 10934644
[TBL] [Abstract][Full Text] [Related]
46. Identification of a novel mutation of SH3BP2 in cherubism and demonstration that SH3BP2 mutations lead to increased NFAT activation.
Lietman SA; Kalinchinko N; Deng X; Kohanski R; Levine MA
Hum Mutat; 2006 Jul; 27(7):717-8. PubMed ID: 16786512
[TBL] [Abstract][Full Text] [Related]
47. NFATc1 induces osteoclast fusion via up-regulation of Atp6v0d2 and the dendritic cell-specific transmembrane protein (DC-STAMP).
Kim K; Lee SH; Ha Kim J; Choi Y; Kim N
Mol Endocrinol; 2008 Jan; 22(1):176-85. PubMed ID: 17885208
[TBL] [Abstract][Full Text] [Related]
48. Primary human bone marrow adipocytes support TNF-α-induced osteoclast differentiation and function through RANKL expression.
Goto H; Hozumi A; Osaki M; Fukushima T; Sakamoto K; Yonekura A; Tomita M; Furukawa K; Shindo H; Baba H
Cytokine; 2011 Dec; 56(3):662-8. PubMed ID: 21963155
[TBL] [Abstract][Full Text] [Related]
49. [Research on regulation mechanism of osteoclast differentiation].
Song CY; Peng B; Shen JY; Jin HT; Xiao LW; Tong PJ
Zhongguo Gu Shang; 2015 Jun; 28(6):580-4. PubMed ID: 26255490
[TBL] [Abstract][Full Text] [Related]
50. Akt induces osteoclast differentiation through regulating the GSK3β/NFATc1 signaling cascade.
Moon JB; Kim JH; Kim K; Youn BU; Ko A; Lee SY; Kim N
J Immunol; 2012 Jan; 188(1):163-9. PubMed ID: 22131333
[TBL] [Abstract][Full Text] [Related]
51. Effects of pulsed electromagnetic fields on the expression of NFATc1 and CAII in mouse osteoclast-like cells.
He J; Zhang Y; Chen J; Zheng S; Huang H; Dong X
Aging Clin Exp Res; 2015 Feb; 27(1):13-9. PubMed ID: 24869857
[TBL] [Abstract][Full Text] [Related]
52. Ca2+-NFATc1 signaling is an essential axis of osteoclast differentiation.
Negishi-Koga T; Takayanagi H
Immunol Rev; 2009 Sep; 231(1):241-56. PubMed ID: 19754901
[TBL] [Abstract][Full Text] [Related]
53. M-CSF priming of osteoclast precursors can cause osteoclastogenesis-insensitivity, which can be prevented and overcome on bone.
De Vries TJ; Schoenmaker T; Aerts D; Grevers LC; Souza PP; Nazmi K; van de Wiel M; Ylstra B; Lent PL; Leenen PJ; Everts V
J Cell Physiol; 2015 Jan; 230(1):210-25. PubMed ID: 24962140
[TBL] [Abstract][Full Text] [Related]
54. Expression of receptor activator of NF-κB ligand and osteoprotegerin in peripheral giant cell granulomas of the jaws.
Fanourakis G; Lazaris AC; Krithinakis S; Tosios KI; Sklavounou A; Tseleni-Balafouta S
J Oral Pathol Med; 2010 Oct; 39(9):687-9. PubMed ID: 20701665
[TBL] [Abstract][Full Text] [Related]
55. Osteoclast formation elicited by interleukin-33 stimulation is dependent upon the type of osteoclast progenitor.
Eeles DG; Hodge JM; Singh PP; Schuijers JA; Grills BL; Gillespie MT; Myers DE; Quinn JM
Mol Cell Endocrinol; 2015 Jan; 399():259-66. PubMed ID: 25458701
[TBL] [Abstract][Full Text] [Related]
56. Effect of a rare genetic variant of TM7SF4 gene on osteoclasts of patients with Paget's disease of bone.
Laurier E; Amiable N; Gagnon E; Brown JP; Michou L
BMC Med Genet; 2017 Nov; 18(1):133. PubMed ID: 29145829
[TBL] [Abstract][Full Text] [Related]
57. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
Irie A; Takami M; Kubo H; Sekino-Suzuki N; Kasahara K; Sanai Y
Bone; 2007 Aug; 41(2):165-74. PubMed ID: 17560185
[TBL] [Abstract][Full Text] [Related]
58. Inhibition of receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast formation by pyrroloquinoline quinine (PQQ).
Odkhuu E; Koide N; Haque A; Tsolmongyn B; Naiki Y; Hashimoto S; Komatsu T; Yoshida T; Yokochi T
Immunol Lett; 2012 Feb; 142(1-2):34-40. PubMed ID: 22193059
[TBL] [Abstract][Full Text] [Related]
59. Aminocoumarins inhibit osteoclast differentiation and bone resorption via downregulation of nuclear factor of activated T cells c1.
Zheng T; Noh AL; Park H; Yim M
Biochem Pharmacol; 2013 Feb; 85(3):417-25. PubMed ID: 23123663
[TBL] [Abstract][Full Text] [Related]
60. Inhibition of RANKL-stimulated osteoclast differentiation by Schisandra chinensis through down-regulation of NFATc1 and c-fos expression.
Kim EJ; Lee H; Kim MH; Yang WM
BMC Complement Altern Med; 2018 Oct; 18(1):270. PubMed ID: 30285722
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
